Assessment of micro-bleeding after prophylaxis with enoxaparin or rivaroxaban against venous thromboembolic disease following hip and knee arthroplasty.

Trial Profile

Assessment of micro-bleeding after prophylaxis with enoxaparin or rivaroxaban against venous thromboembolic disease following hip and knee arthroplasty.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Most Recent Events

    • 21 Apr 2016 Status changed from recruiting to completed.
    • 10 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top